DIAGNOSTICS
outcome and tackling unequal outcomes and access.18
Despite the positive strides being taken to radically reform the NHS and tackle the many issues the healthcare sector currently faces; we must still be mindful of the incredibly delicate situation the NHS is currently in with COVID-19, paired with the growing elective care crisis. It is absolutely critical that we get integrated and community care right. So, how do we a) tackle rampant health inequality across England to improve patient outcomes and relieve pressure on the NHS, b) achieve fully integrated and community care and c) navigate the ongoing challenges caused by COVID-19 and the growing backlog of elective treatments? The answer lies within the delivery of Community Diagnostic Hubs – specifically modular and mobile complexes.
There are expansive benefits to investing in modular buildings created using modern methods of construction for healthcare. The main reasons for adopting a modular and mobile building approach to delivering CDHs include: accelerated delivery; reduced capital cost; flexible design that can be tailored to meet individual needs; construction that is less labour intensive and more efficient; better quality compared with onsite construction, sustainability, and the potential to be reconfigured in the future to meet
changing needs.
Modular and mobile facilities combined are extremely flexible, in the sense that they can have all core functions in situ with interchangeable spokes dedicated to delivering the diagnostic and therapy treatments, which can easily be swapped in and out to respond to changes in demand. The ability to quickly adapt facilities will allow CDHs to address the rapidly changing needs of the community and help to clear waiting lists at a faster rate. To demonstrate this in real terms,
Vanguard Healthcare Solutions recently led the delivery of a modular healthcare facility in Roehampton to support St Georges University Hospital Trust with reducing demand at their main acute facility and increasing demand in the area. Vanguard was able to design and deliver a facility containing a reception, four consultation rooms, theatre rooms and associated support space in less than six months. The modular facility is disconnected from the main hospital and located within a disused car park – transforming this disused land within the community into a valuable asset that will enable quicker and more efficient access to healthcare services. Investing in community healthcare that is modular and mobile will also help us to tackle health inequality, as we are able
to deliver a greater number of healthcare facilities located in more accessible locations. A report by the NHS England in 2018 stated that ‘people are experiencing poorer outcomes from poorer access to services’19 – delivering CDHs will enable us to tackle this issue but delivering modular and mobile CDHs will enable us to tackle it more effectively. As modular and mobile healthcare can be delivered on a wide range of sites in comparison to typical brick and mortar facilities, we are able to utilise existing community spaces to deliver exceptional care.
Delivering traditional facilities requires the existence of appropriate sites, and this can often be a challenge – particularly in densely populated areas like Central London where development land is harder to come by. Modular facilities allow us to deliver healthcare where it is needed – rather than delivering it in a few select spaces that there is opportunity to. That means we can deliver more facilities, in more locations, bringing healthcare to the people and making it easier and quicker to access. By improving access to healthcare facilities, individuals are empowered to take control of their own health, supporting early detection, treatment and overall better public health outcomes. Modular facilities benefit from following a standardised industrial process,20
rather
Supporting Efficiencies in Gastroenterology Diagnostics
Non-invasive faecal diagnostic tests can provide valuable information to cost-effectively triage patients presenting with gastrointestinal symptoms.
They help support clinical decision making whilst relieving demands on endoscopy resources.
Calprotectin Testing ■
■ Differentiate between IBD and IBS
Widest range of assay formats: from single tests to automated high throughput methods
■ Laboratory, Point-of-Care & Patient Home Testing ■ Standardised measurements across the range
Faecal Immunochemical Testing ■
Colorectal cancer patient pathway triage ■
Hygienic, convenient sample collection for patients encourages test uptake
■ Complete patient packs to suit your service ■ Automated, dedicated laboratory testing platform
For more information, to discuss your requirements or organise an evaluation please contact:
digestivedx@alphalabs.co.uk
Tel: 02380 483000
Email:
digestivedx@alphalabs.co.uk Web:
www.alphalabs.co.uk
CSJ_Gastro_Half_Page_August_2021.indd 1 AUGUST 2021 05/07/2021 14:23:25
WWW.CLINICALSERVICESJOURNAL.COM l 85
▲
Find out more at
www.alphalabs.co.uk
Name
00000024 LOT 107AIE 2021.05.31 Date of Birth Date of Sample M / F
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88
